Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors
about
Quinoxaline 1,4-di-N-Oxides: Biological Activities and Mechanisms of ActionsDefining normoxia, physoxia and hypoxia in tumours-implications for treatment responseWhat is the best treatment for patients with human papillomavirus-positive and -negative oropharyngeal cancer?Q6, a novel hypoxia-targeted drug, regulates hypoxia-inducible factor signaling via an autophagy-dependent mechanism in hepatocellular carcinomaHypoxia-Targeted Drug Q6 Induces G2-M Arrest and Apoptosis via Poisoning Topoisomerase II under HypoxiaIsotopic labeling experiments that elucidate the mechanism of DNA strand cleavage by the hypoxia-selective antitumor agent 1,2,4-benzotriazine 1,4-di-N-oxideMetabolic targeting of HIF-dependent glycolysis reduces lactate, increases oxygen consumption and enhances response to high-dose single-fraction radiotherapy in hypoxic solid tumors.ABC transporters in CSCs membranes as a novel target for treating tumor relapse.Toward hypoxia-selective DNA-alkylating agents built by grafting nitrogen mustards onto the bioreductively activated, hypoxia-selective DNA-oxidizing agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancerSix degrees of separation: the oxygen effect in the development of radiosensitizers.Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents.Combined hyperthermia and radiotherapy for the treatment of cancer.18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft modelThe Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.Targeting the metabolic microenvironment of tumors.Lessons learned from radiation oncology clinical trials.Microenvironment and radiation therapyBioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.Recent updates in utilizing prodrugs in drug delivery (2013-2015).Radiation enhances the therapeutic effect of Banoxantrone in hypoxic tumour cells with elevated levels of nitric oxide synthase.Hypoxia-activated prodrugs: paths forward in the era of personalised medicine.Synthesis and biological evaluation of 3-aryl-quinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives as hypoxic selective anti-tumor agents.Efficient Protocol for the Identification of Hypoxic Cell Radiosensitisers.Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in Mice.Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinomaBystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell CulturesCopper-64: a real theranostic agentHypoxia-activated prodrugs and redox-responsive nanocarriers
P2860
Q26752388-7DBD5B7C-943B-4C15-9C07-F98DD3DA4DFAQ27009437-BC423E45-5819-47FB-8564-86F12EB18E9EQ27026269-C869D0F6-7F57-4C68-AF03-46F23FDBE790Q28301777-2125E63C-6B8E-4332-99CB-8CB4C0597142Q28551450-9F450DA9-BFD8-43A6-B12D-B756D3481E79Q33575435-28FB1F78-5DB0-488A-AF79-6211227489DAQ33805580-B9A34802-BF06-419D-95E7-6B42D371404BQ33879326-5711698C-A693-4586-9B67-F9582F592E18Q34061361-864CA2D7-B305-4281-857F-117221CBDB65Q34756921-76BEE3F5-88D7-4C74-9445-1C2B1FCC41F0Q35116798-5D53AFDA-0282-4D3E-9A9F-78209FEE8954Q36459685-BECDE0C7-B091-48D8-A630-F895299C2406Q37148144-B75DE959-3490-41EE-BC07-A610F482EAFDQ37165297-0090E936-67AD-444A-9C65-4C827A88E87DQ37217739-BDE415FC-64FA-464A-9529-5F95257A8372Q37229190-B5E3D2F7-40F6-4D9F-A8F9-3C17CF3F46B4Q37662359-94A48621-2361-491D-BB68-18C7246230FCQ38091084-0C4C9C9B-86E6-4B42-8F17-85D0C6E466E2Q38120850-4B0BF18A-05B8-44FE-901E-73349FDC3546Q38177279-9853D5C1-FA03-48CA-9975-15E378BE3706Q38702949-F195CE1A-EEAF-4037-8F70-E84D2F4C32B3Q38722296-D3759D03-7993-4810-993F-2D82E165C92BQ38806173-10B7A232-F6E3-44F1-8E56-A3DA1B0274F0Q39298066-3BF0D1C4-53CC-4B8B-95B2-742B275DECD8Q39668588-7B0E36C5-86AF-4366-9383-A8E25EE14593Q41370914-3B7AF755-B283-434A-BE72-6DB3FC3F95C3Q56889832-9D1D4321-4744-4EA1-835A-FDAE617B1611Q57073801-2A75349B-7E63-4024-AE41-22AC4F083BA0Q57484995-E792D6E3-B52A-4256-84BB-511DF0211269Q58694676-6EA2D768-9345-48B5-8A10-913224C34223
P2860
Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Pharmacokinetic/pharmacodynami ...... hypoxic cell killing in tumors
@ast
Pharmacokinetic/pharmacodynami ...... hypoxic cell killing in tumors
@en
type
label
Pharmacokinetic/pharmacodynami ...... hypoxic cell killing in tumors
@ast
Pharmacokinetic/pharmacodynami ...... hypoxic cell killing in tumors
@en
prefLabel
Pharmacokinetic/pharmacodynami ...... hypoxic cell killing in tumors
@ast
Pharmacokinetic/pharmacodynami ...... hypoxic cell killing in tumors
@en
P2093
P2860
P1476
Pharmacokinetic/pharmacodynami ...... hypoxic cell killing in tumors
@en
P2093
Alison Hogg
Annie M Fraser
Bronwyn G Siim
H D Sarath Liyanage
J Martin Brown
Jagdish K Jaiswal
Kevin O Hicks
Mary Jo Dorie
Rita Patel
William A Denny
P2860
P304
P356
10.1158/1078-0432.CCR-10-1439
P407
P577
2010-08-20T00:00:00Z